Results
|
1.
|
|
|
2.
|
|
|
3.
|
Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer. MedStar authors:
Year: 2022
Citation: - European Journal of Cancer. 178:70-81, 2022 Oct 07.
Medline publication type:
All authors: - Aguila C, Dang CT, Gianni L, Heeson S, Kuemmel S, Liu H, Loibl S, Macharia H, O'Shaughnessy J, Restuccia E, Schneeweiss A, Swain SM, Tan AR, Yang K
|
|
4.
|
Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review & bayesian network meta-analysis. MedStar authors:
Year: 2022
Citation: - European Journal of Cancer. 169:82-92, 2022 Jul.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
All authors: - Abdelfattah OM, Abela GS, Addison D, Awad AK, Barac A, Fradley MG, Gerew M, Ghaith HS, Guha A, Moustafa K, Munir M, Sayed A, Shazly O
|